Compare Accenture plc (ACN) vs Amgen, Inc. (AMGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Amgen, Inc. — how do they compare? Accenture plc trades at $138.7 (market cap $86.98B), while Amgen, Inc. trades at $368.87 (market cap $198.67B). The key difference: Amgen, Inc. is far larger — about 2.3× Accenture plc's market cap, and Accenture plc pays the higher dividend (4.59%). Which is the better fit depends on your goals.
| ACN | AMGN | |
|---|---|---|
Market Cap | $86.98B | $198.67B |
Sector | Technology | Health |
52-Week High | $303.33 | $388.16 |
52-Week Low | $124.41 | $271.18 |
Enterprise Value | $85.20B | $243.95B |
Dividend Yield | 4.59% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
Amgen (AMGN) trades at $368.10, down 1.62% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net income margin of 20.96% and has beaten earnings estimates for three consecutive quarters. Recent news includes a favorable court ruling blocking a price cap on Enbrel and analyst upgrades, though regulatory challenges for Tavneos in Europe pose headwinds. Cash flow from operations remains robust at nearly $10 billion annually.
The outlook for AMGN is positive with steady revenue growth and high margins, but investors face risks from patent expirations and regulatory scrutiny. Analyst consensus is bullish with a $358.25 price target, though the current price exceeds this, suggesting near-term consolidation may occur. The company's strong cash generation supports dividend payments, but high debt levels require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
